Provided by Tiger Trade Technology Pte. Ltd.

GT Biopharma Inc.

5.96
-0.2400-3.87%
Pre-market: 5.960.00000.00%07:07 EDT
Volume:31.77K
Turnover:189.79K
Market Cap:10.75M
PE:-0.45
High:6.22
Open:6.20
Low:5.80
Close:6.20
52wk High:28.75
52wk Low:4.91
Shares:1.80M
Float Shares:1.74M
Volume Ratio:0.87
T/O Rate:1.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.2195
EPS(LYR):-156.2099
ROE:-113.52%
ROA:-158.16%
PB:3.01
PE(LYR):-0.04

Loading ...

Feb 09, 2021

Correspondence

CORRESP [Cover] - Correspondence
Feb 09, 2021

Major Issues Report

8-K - Current report
Feb 09, 2021

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Feb 08, 2021

Correspondence

CORRESP [Cover] - Correspondence
Feb 08, 2021

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Feb 08, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 05, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 02, 2021

Major Issues Report

8-K - Current report
Feb 02, 2021

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Jan 19, 2021

Major Issues Report

8-K - Current report
Dec 31, 2020

Major Issues Report

8-K - Current report
Dec 28, 2020

Major Issues Report

8-K - Current report
Dec 23, 2020

Major Issues Report

8-K - Current report
Dec 11, 2020

Public Prospectus

S-1 - General form for registration of securities under the Securities Act of 1933
Nov 13, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 09, 2020

Major Issues Report

8-K - Current report
Nov 04, 2020

Major Issues Report

8-K - Current report
Oct 06, 2020

Major Issues Report

8-K - Current report
Sep 22, 2020

Major Issues Report

8-K - Current report
Aug 18, 2020

[Rev.]Quaterly Report

10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)]